Abstract
Spontaneous bacterial peritonitis (SBP) is the most common infection in end-stage liver disease patients. SBP is defined as an ascitic fluid infection with a polymorphonuclear leucocyte count ≥ 250/mm 3 without an evident intra-abdominal surgically treatable source. Several mechanisms contribute to SBP occurrence, including translocation of gut bacteria and their products, reduced intestinal motility provoking bacterial overgrowth, alteration of the gut's barrier function and local immune responses. Historically, Gram-negative enteric bacteria have been the main causative agents of SBP, thereby guiding the empirical therapeutic choice. However, over the last decade, a worryingly increasing prevalence of Gram-positive and multi-drug resistant (MDR) SBP has been seen. Recently, the microbiological spectrum of SBP seems to have changed in Europe due to a high prevalence of Gram-positive bacteria (48%-62%). The overall proportion of MDR bacteria is up to 22%-73% of cases. Consequently, empirical therapy based on thirdgeneration cephalosporins or amoxicillin/clavulanic acid, can no longer be considered the standard of care, as these drugs are associated with poor outcomes. The
INTRODUCTION
The development of abdominal ascites is the most frequent complication in cirrhotic patients [1] , and infected ascites, better known as spontaneous bacterial peritonitis (SBP), is the most common infection in these patients, together with urinary tract infections [2] . SBP is defined as a polymorphonuclear (PMN) leucocyte count ≥ 250/mm 3 , with or without positive ascitic culture and the absence of other sources of sepsis in the peritoneum or adjacent tissues [3] . SBP is a distinct clinical entity, as opposed to bacteriascites (positive ascitic culture with PMN < 250/mm 3 , not needing therapy in cases of no accom panying symptoms) and secondary bacterial peritonitis, which are usually polymicrobial and linked to the infla mmation or perforation of an abdominal organ [3] . Several mechanisms contribute to the occurrence of SBP, including translocation of gut bacteria and their products, reduction of intestinal motility provoking bacterial overgrowth, alteration of the gut's barrier function and local immune responses [4] . These premises explain why historically Gramnegative bacteria (GNB) have been the main causative agents of SBP, thereby guiding the empirical therapeutic choice [5] . However, over the last decade the prevalence of Grampositive bacteria (GPB) and multidrug resistant (MDR) SBP has increased worryingly [6] . Important driving factors for this epidemiological change have been the extensive use of quinolones, as a prophylactic measure, and the increasing degree of instrumentalization of patients suffering from cirrhosis [7] . Consequently, empirical therapy based on thirdgeneration cephalosporins (3GCs) or amoxicillin/ clavulanic acid, especially within a healthcare setting, can no longer be considered the standard of care due to poor outcomes [8] .
Bacterial infections are the primary cause of death in patients with endstage liver disease (ESLD), and require timely and appropriate treatment [9] . Thus, the aim of this review is to describe, with an epidemiological focus, the evidence behind this rise in Grampositive and MDR SBP from 2000 to present, and illustrate potential targeted therapeutic strategies.
EPIDEMIOLOGY OF SBP: CHANGE OF PARADIGM
Globally, since 2000, there has been an increasing relevance of the role of GPB with respect to SBP ( Figure  1) . A description of this change follows, according to a geographical criterion.
Asia
Before 2000, GNB were, in consistency with the previous literature [10] , the most prevalent etiologic cause of SBP in Asian cohorts of SBP patients. Then, changes occurred, but in a distinct fashion from country to country. In a retrospective study conducted in South Korea, which reviewed records of individuals diagnosed with SBP in 1995, 1998 and 1999, the rate of GPB was just 18.6% (44/237), with just 5 cases of infection by Staphylococcus aureus and 3 by Enterococcus spp., while the majority of GPB were represented by Streptococcus spp. [11] . These data were substantially confirmed by another South Korean retrospective study (episodes referring to the period from October 1998 to August 2003) that showed a proportion of GPB equal to 20.8% (22/106); no strains of S. aureus were detected, but there were 16 streptococci and 8 enterococci [12] . In a further South Korean retrospective study, which analysed cases from Janua ry 2002 to December 2004, the prevalence of GPB was also low; the bacterial isolates totalled 204 and S. aureus, Enterococcus spp. and Streptococcus spp. accounted for 3.9% (8/204), 3.9% (8/204) and 8.8% (18/204), respectively [13] . In addition, Heo et al [14] found a marginal proportion of GPB in their [16] . On the contrary, in China, the epidemiological shift towards GPB has been more apparent. In a retrospective study of 98 patients, 48 from 1996 to 2002, and 50 from 2003 to 2009, the proportion of GPB passed from 27% (13/48) to 53% (26/49) ; the rate of staphylococci also increased from 14% (7/48) to 37% (18/49), but with only 1 case of methicillinresistant S. aureus (MRSA) [17] . More importantly, inhospital mortality was greater among GPBSBP than GNBSBP cases (26% vs 11%, namely 7 deaths vs 2 deaths), although the result was not significant (P = 0.20) [17] . In a subsequent retrospective study conducted in China, which reviewed medical records from 2011 to 2013, Li et al [18] [18] . More recently in a Chinese study, performed to compare the microbiological profiles of NSBP and community acquired SBP (CASBP), 575 strains were isolated from January 2014 to December 2014. In the CASBP cases, the most frequently isolated pathogens were Escherichia coli (E. coli) (27.4%), coagulasenegative staphylococci (22%), Klebsiella pneumoniae (13.7%), Enterococcus spp. (9%) and Streptococcus (8.2%). In the NSBP, the most frequently isolated pathogens were E. coli (25.9%), coagulasenegative staphylococci (23.4%), K. pneumoniae (2.5%), Enterococcus spp. (16.6%) and Streptococcus (6.2%). In the statistical analysis, there were no significant differences in the distributions of GPB between the CA and NSBP. In contrast, compared with the CASBP, the distribution of enterococci was increased in the NSBP (9.0% vs 16.6%, P < 0.05) [19] . Different results have come from studies in other Asian countries. In Iran, a prospective study (from Nov ember 2005 to December 2007) showed a proportion of GPB equal to 27.3% (12/44) [20] . A similar result (28.6%, 90/314) was found in another study conducted in Iran (from April 2005 to September 2011) [21] . A small cohort from Pakistan showed a relatively low percentage of GPB: 25% (3/12) in a 2007 prevalence study [22] .
Africa
In an Egyptian prospective cohort, the burden of GPB turned out to be as high as 73.2%, namely 30 [23] . In contrast, a retrospective study conducted in Nigeria, which reviewed medical records from August 2009 to July 2010, showed a much smaller proportion of GBP, which although not marginal was equal to 31.8% (7/22) [24] .
South America
In a Brazilian retrospective study referring to a 5year period (from November 2001 to November 2006), a significant rate of GPB emerged despite the lack of a complete microbiological profile of 63 cases [Streptococcus spp. 23.8% (15/63), S. aureus 7.9% (5/63)] [25] . A more recent and prospective multicentre study conducted in Argentina, from March 2011 to April 2012, showed a clear predominance of GPB over GNB [21/33 (63.6%)]; of note, the study, which aimed at investigating the potential association between proton pump inhibitors (PPIs) and SPB, showed no significant difference with regard to PPIs' consumption and duration between patients with and without SBP (as well as with and without other infections) nor with regard to the type of bacteria [26] .
North America
A high number of GPB was found in a United States retrospective study, referring to medical records from July 2009 and November 2010: 80% (8/10), including two vancomycinresistant enterococci (VRE) [27] . The high impact of GPB in SBP in North America has been further confirmed in a Canadian retrospective cohort that reviewed cases from February 2003 to May 2011; the data indicated that 57.1% (44/77) and 34.1% of these strains (15/44) were resistant to 3GCs (acquired or intrinsic resistance) [28] .
Europe
In a prospective French study conducted from January 1996 to March 2001, GPB accounted for 68.3% (125/ 183) of ascitic fluid infections [29] . GPB cases were mainly explained by enterococci (43/125), streptococci (43/125) and S. aureus (36/125); the large majority of the latter (94.4%, 34/36) were MRSA [29] . In that study, the multivariate analysis showed that an infection provoked by S. aureus (while taking into account cases of bacteraemia) was independently linked to a higher mortality rate in cirrhotic patients (OR = 2.845, 95%CI: 1.4215.695, P = 0.031) [29] . In France, Grampositive cocci are today the predominant ascitic fluid microbes, with isolates ranging from 47.4% [30] to 56.1% of cases [31] . Data from a Spanish study, conducted from April 1998 to April 2000, demonstrated a low proportion of GPB (20.3%, 11/54) [32] . In a retrospective study by Ariza et al [33] , reviewing medical records related to a subsequent period from 2001 to 2009, GPB rate was again relevant [35 [33] . In Italy, interesting data stem from a recently published randomized clinical trial (RCT), conducted from 2011 to 2014. The aim of that RCT was to compare ceftazidime to the combination of daptomycin plus meropenem, applied as an empirical treatment of N-SBP (in this case, defined if it occurred > 72 h after hospital admission); in particular, 62.5% (10/16) of culturepositive cases were due to GPB (8 enterococci) [34] . Of note, the broadspectrum regimen proved to be significantly more effective with regard to the primary outcome, namely the resolution of SBP after 7 d of treatment (86.7% vs 25%; P < 0.001); that finding did not come as a surprise, in the light of the total rate of MDR bacteria [37.5% (6/16)] [34] . In Germany, the growing number of GPB was already a touted issue, more than a decade ago. In a prospective cohort from 2002 to August 2006, Umgelter et al [35] found a GPB rate equal to 45.4% (20/44, 10 E. faecium). Again, in Germany, a retrospective cohort covering a 12year period (from January 2001 to November 2011) found a predominance of GPB (53.7%, 65/121), where Enterococcus spp. (28 out of 65 GPB) played a highly relevant role [36] . In the multivariate analysis, use of antibiotics (OR = 3.875, 95%CI: 1.18912.631, P = 0.025) and nosocomial infection (OR = 3.287, 95%CI: 1.3118.243, P = 0.011) were the independent predictors of enterococcal infections, which were associated with higher mortality (12% probability of 90d survival vs 50% in nonenterococcal cases, P = 0.022 by logrank test) in case of treatment with a 3GC or a quinolone [36] . Also, in a more recent German prospective cohort, followed from March 2012 to February 2016, and focusing only on nosocomial and healthcarerelated SBP, GPB were relevant [Staphylococcus spp., Enterococcus spp. and Streptococcus spp. accounted for 40% of cases (20/50)] [37] . Greece was one the first countries to warn about the increasing importance of GPBSBP. Cholongitas et al [38] , in a retrospective evaluation, observed that the rate of GPB went from 25% (5/20) to 59.1% (13/22%) in two subsequent periods of time, from 1998 to 1999 and from 2000 to 2002, respectively. This trend in Greece was confirmed by another retrospective study, including cases from 2008 to May 2011, with 26 episodes out of 47 (55%) due to GPB, most of all streptococci (10 isolates), followed by 6 E. faecalis, 3 E. faecium and 2 S. aureus; neither VRE nor MRSA were detected [6] . In Denmark, a retrospective review of medical re cords from 2000 to 2006 showed a proportion of Gram positive cocci, without considering other GPB, equal to 45.9% (86/187) [39] .
CONTROVERSIES RELATED TO THE DIAGNOSIS OF SBP BY GRAM-POSITIVE

BACTERIA
Although some authors have previously considered the isolation of coagulasenegative staphylococci within ascitic [15, 40, 41] , today the clinical significance of such a finding appears relevant in both nosocomial [19, 34] and community acquired infections [19] . More than 40 years ago, MacGregor and Beaty [42] pro posed guidelines to differentiate contamination from significant positive blood cultures in bacteraemic patients; nowadays guidelines, however, are still lacking in their ability to differentiate contamination from significant positive ascitic cultures. In our opinion, the absence of recommendations based on solid evidence does not justify concluding isolation of coagulasenegative staphylococci as contamination [15] . Future studies are required to establish the hypothetical difference between the contaminants or pathogens.
CURRENT THERAPEUTIC STRATEGIES FOR SBP BY GPB
The current guidelines rely on outdated epidemiology [4345] and take into account neither the increasing prevalence of GPB nor the emerging phenomenon of MDR bacteria as aetiological agents of SBP [46] . Opinion leaders recommend 3GCs [47] or piperacillin/tazobactam, meropenem ± gly copeptide [1] for patients at risk of MDR SBP. The role of piperacillin/tazobactam in the treatment of lifethreatening infections due to extended spectrum betalactamase (ESBL)producing Enterobacteriaceae is a controversial issue [4749] ; moreover, meropenem is active against ESBL producing Enterobacteriaceae but is weakly active against Grampositive cocci [50, 51] . Glycopeptides are active against Grampositive cocci, as well as MDR, but their use is not advisable because of their nephrotoxicity. Acute kidney injury is higher in ESLD patients, it could be related to hemodynamic instability and/or hepatorenal syndrome [52] . Furthermore, the minimum inhibitory concentration (MIC) of vancomycin appears to be shifting upwards in some institutions, a phenomenon known as MIC creep; and, where the MIC increase occurs, treatment failure is common [53, 54] . Teicoplanin MIC creep has also been described; but, regardless, when it is administered intravenously it does not achieve therapeutic concentration in the ascitic fluid [55] . Antibiotics active against VRE are linezolid, tigecycline, and daptomycin. Linezolid is not recommended in the majority of ESLD and SBP patients because of high frequency thrombocytopenia [56] . A tigecycline dose adjustment is requested in patients with severe hepatic impairment [57, 58] . Daptomycin is a lipopeptide active against MDR GPB, including drugresistant and drugsusceptible S. aureus and VRE [59] . Decreased susceptibility to daptomycin has been reported in drugresistant S. aureus; it is frequently accompanied by a paradoxical decrease in betalactam resistance, a process known as the "seesaw" effect. Despite the observed discordance in resistance phenotypes, the combination of daptomycin/betalactams has been proven clinically effective for the prevention and treatment of infections due to daptomycinresistant S. aureus strains [60, 61] . Therefore, daptomycin monotherapy should not be used for the treatment of SBP due to MRSA, unless the isolate is likely to be fully susceptible [62] . The combination of daptomycin plus ceftaroline is highly active against MRSA, the potent bactericidal activity appears to be sufficiently robust to allow rapid de escalation to single ceftaroline with daptomycin sparing [63] . Furthermore, ceftaroline in combination with daptomycin restores daptomycin activity against daptomycinresistant VRE strains [64] . Aminoglycoside antibiotics, especially gentamicin, are used in combination with ampicillin for the treatment of enterococcal systemic infections [65] . Despite rigorous patient monitoring, nephrotoxicity appears in 10%25% of therapeutic courses [66] . Therefore, their use is not advisable in cirrhotic patients. In recent years, an alternative treatment with ampicillin plus ceftriaxone has proved to be safer than gentamicin in combination with ampicillin [67] . In ESLD patients, the combination of ampicillin plus ceftriaxone should be used for SBP due to enterococci, regardless of aminoglycoside resistancelevel status. The 20 th century has been characterized by the dramatic effect of the largescale use of antibiotics after their discovery, saving millions of lives [68] . Unfortunately, natural selection and misuse of antibiotics, both in human beings and in animals, have led to the development of difficult-totreat infections by MDR bacteria, also known as superbugs, the nightmare of the new century [69] . Research efforts by pharmaceutical companies are not keeping pace with the worldwide spread of superbugs and this has prompted new strategies to optimize existing resources, such as the reviving of old antibiotics [70] , the implementation of antimicrobial stewardship programs [71, 72] , and the judicious use of new antiinfective agents [73] . However, the epidemiology of bacterial infections has a huge inter centre variability and the therapeutic approach should be inspired by the principle of "one size does not fit all", which obviously also applies to SBP [74] . In other words, the current challenge is to accurately identify patients with SBP for whom empirical broadspectrum therapy would be appropriate, with special attention to MDRGPB in contexts where their prevalence is relevant [74] . Some risk factors are well established. The setting of acquisition (nosocomial or healthcarerelated vs com munityacquired) and the history of exposition to antibiotics, such as betalactams and/or quinolones, are probably the main ones [75, 76] . Exposure to quinolones, largely used to prevent SBP in cirrhotic patients, is a significant risk factor for MRSA infections [77, 78] . Moreover, antibiotics administered within the past 30 d before SBP diagnosis and a lower sepsisrelated organ failure assessment (commonly known as SOFA) score proved to be significantly associated with SBP by GPB in a cohort of 77 patients [79] . The impact of MDRGPB on SBP patient mortality is not well investigated; recently, we performed a systematic review aimed at summarizing the evidence from the literature concerning Li et al [18] World J Gastroenterol Shi et al [19] Sci Rep 2017 2014 RC, single centre China, Tertiary Hospital 293/575 (50.9) Asia -Other countries Kamani et al [20] BMC Oladimeji et al [24] Pan Terg et al [26] J [27] Clin Gastroenterol Hepatol Chaulk et al [28] Can J Gastroenterol Hepatol Piano et al [34] Hepatology 2016 2011-2014 RCT, multicentre Italy 10/16 (62.5) Umgelter et al [35] Infection 2009 Reuken et al [36] Aliment Pharmacol Ther Lutz et al [37] Eur Cholongitas et al [38] Liver Novocic et al [39] Scand J Gastroenterol Fiore M et al . Gram-positive SBP antimicrobial therapy the epidemiology of nosocomial cases of SBP, in order to highlight the importance of MDR bacteria outcome; of the initial 2556 manuscripts retrieved, only 9 were included in the qualitative analysis, and a quantitative analysis on mortality was not possible [80] . Risk factors could be integrated into predictive models of mortality in individuals with SBP so as to further help identify patients in need of more aggressive therapeutic strategies from the very start of the infective process [81] .
FUTURE PERSPECTIVES
CONCLUSION
GPB are increasingly important as causative agents of SBP. In some contexts, they even supersede GNB as the main cause of this infection (Table 1 describes the main features of included studies). In parallel with this phenomenon, physicians have to face the rise of superbugs, both among GNBs and GPBs. In presence of particularly worrisome epidemiological data and other risk factors for superbug infections, a broadspectrum empirical approach is required, encompassing antibiotics with wellestablished activity against pathogens, such MRSA and VRE, pending the results of microbiological tests that would allow a deescalation strategy whenever possible.
On the basis of the current literature, we propose a treatment algorithm for SBP due to GPB (Figure 2) . If an ESLD patient with ascites is "symptomatic" for SBP (temperature above 38 ℃ or below 36.5 ℃, chills, abdominal tenderness, arterial hypotension, developing or worsening hepatic encephalopathy, gastrointestinal bleeding within the previous 15 d) it is necessary to perform a Periscreen strip on the ascitic fluid [30] . If the Periscreen strip is positive the patient requires immediate hospitalization with comparison of this result with cytology and immediate microbiological cultures. A culture of ascitic fluid and blood should systematically be carried out at the bedside [34] . Empiric antibacterial therapy (EAT) should be initiated after obtaining appropriate cultures. 3GCs should not be used in clinical settings and/or centres with a high prevalence of MDR bacteria. ESLD patients with SBP in clinical settings and/or centres with a high prevalence of VRE, MRSA and ESBL should immediately receive broadspectrum EAT [82] . An appropriate treatment protocol should include daptomycin plus ceftaroline and meropenem [83] . When the culture is positive and susceptibility data are available, an antibiotic with a narrower spectrum should be promptly initiated (early deescalation strategy); this strategy limits the selection of antibiotic resistances and saves on costs [83] .
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